Over half of new cancer drugs 'show no benefits' for survival or wellbeing

Of 48 cancer drugs approved between 2009-2013, 57% of uses showed no benefits and some benefits were 'clinically meaningless', says BMJ study

Most cancer drugs that have recently arrived on the market have come with little evidence that they boost the survival or wellbeing of patients, research reveals.

Forty-eight cancer drugs were approved by the European Medicines Agency between 2009 and 2013 for use as treatments in 68 different situations.